Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02511132
Title A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gradalis, Inc.
Indications

Ewing sarcoma of bone

extraosseous Ewing sarcoma

Therapies

FANG vaccine

Docetaxel + Gemcitabine

FANG vaccine + Irinotecan + Temozolomide

Age Groups: adult | child | senior
Covered Countries USA


No variant requirements are available.